Trial ID:NCT03955939
Protocol #:19-314
Condition(s):Metastatic Breast Cancer
Phase:I
Principal Investigator:Tolaney, Sara, M
Site Investigator(s):Wander, Seth, A.
Site Research Nurse(s):Selland, Britt,
Trial Description:
The reason for this study is to determine the recommended phase 2 dose of the study drug
LY3295668 erbumine in participants with breast cancer that has spread to other parts of the
body.
Eligibility Requirements:
- Participant must have hormone receptor positive and HER2 negative metastatic breast
cancer
- Participant must have progressed on at least 1 line of endocrine therapy and 1 cyclin
dependent kinase (CDK)4/6 inhibitor
- Participant must be able and willing to undergo mandatory tumor biopsy
- Participant must have normal organ function
- Participant must be able to swallow capsules
Exclusion Criteria:
- Participant must not have had prior chemotherapy for mBC. Chemotherapy in the
adjuvant/neoadjuvant setting is permitted
- Participant must not be currently enrolled in a clinical study
- Participant must not have another serious medical condition
- Participant must not have previously received an aurora kinase inhibitor
Protocol #: 19-314